Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUTO1-SL2 obe-cel in severe refractory systemic lupus erythematosus with active lupus nephritis
2024-519941-32-00Phase 2Authorised
- Sponsor
- Autolus Therapeutics plc
- Start
- Nov 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of obecabtagene autoleucel in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Autolus Therapeutics plc. Primary endpoint: Complete renal response at Month 6. Planned start Nov 2025; status: authorised.
02
Drugs
obecabtagene autoleucel
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on 2024-519941-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519941-32-00.